Lung cancer screening with low-dose chest computed tomography (CT) may detect more than just lung cancer. As new research in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.231602 shows, these CTs can identify coronary… read more.
Azurity Pharmaceuticals announced that the FDA has approved Danziten, the first and only nilotinib with no mealtime restrictions indicated for adult patients with newly diagnosed Philadelphia chromosome positive… read more.
CG Oncology, Inc, a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that four Trials… read more.
BMS announced the presentation of more than 90 data disclosures, including 18 oral presentations, across company-sponsored studies, investigator-sponsored studies and collaborations from its hematology and cell therapy research… read more.
Adding treatment with pembrolizumab to standard of care in patients with advanced soft tissue sarcoma of the limb appears to significantly improve disease-free survival, researchers reported on Nov…. read more.
There is a lung cancer screening test that is saving lives – and yet most people who could be getting the test have never heard of it or… read more.
Quitting smoking within six months after a cancer diagnosis adds an average of two years to a patient’s life. With this information in hand, all cancer centers have… read more.
Plus Therapeutics a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will have multiple opportunities to present data at the… read more.
Although breast cancer is the most common non-skin cancer diagnosed in women, finding support during treatment and through survivorship can be incredibly challenging. An analysis of posts from… read more.
Bayer announced the submission of an application to the European Medicines Agency (EMA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use… read more.
An investigative immunotherapy regimen for advanced Hodgkin lymphoma has increased the survival rate from 80 percent to 92 percent, researchers reported on Oct. 17, 2024 in the NEJM/New… read more.
Janssen-Cilag International NV, a Johnson & Johnson company, announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval for an indication… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
